Lewy Body Dementia

🧠 Standard of Care & Symptoms

Lewy Body Dementia (LBD) is a progressive, neurodegenerative disorder characterized by abnormal aggregates of alpha-synuclein in the brain. It is the second most common form of degenerative dementia in older adults, encompassing Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD).

• Presentation: Core clinical features.
  • *Cognitive Fluctuations:* Pronounced variations in attention, alertness, and cognitive function. A patient may range from highly coherent to severely confused or somnolent within hours.
  • *Visual Hallucinations:* Recurrent, detailed, and structured visual hallucinations (typically of people or animals), which are often well-tolerated by the patient.
  • *Spontaneous Parkinsonism:* Motor features including bradykinesia (slowness of movement), resting tremor, muscle rigidity, and a shuffling gait. These typically present concurrently with or after cognitive decline.
  • *REM Sleep Behavior Disorder (RBD):* Parasomnia where patients physically act out their dreams (vocalizations, arm flailing, thrashing) due to loss of normal muscle atonia during REM sleep.
  • *Autonomic Dysfunction:* Spontaneous orthostatic hypotension (blood pressure drop upon standing), urinary incontinence, and severe constipation.

🧬 Diagnostics & Neurotransmitter Pathology

Diagnosis is based on McKeith clinical criteria, DaTscan neuroimaging, and polysomnography findings.

• Diagnostic Markers: Key criteria.
  • DaTscan (Dopamine Transporter Imaging): Single-photon emission computed tomography (SPECT) imaging using I-123 ioflupane. Shows reduced dopamine transporter uptake in the striatum (caudate and putamen), confirming dopaminergic deficit.
  • Brain MRI: Demonstrates relative preservation of the hippocampi and temporal lobes compared to Alzheimer's Disease, despite comparable degrees of global cognitive impairment.
  • Polysomnography: Confirms REM sleep without atonia (RSWA), establishing a definitive diagnosis of REM Sleep Behavior Disorder.

Pathophysiology of Alpha-Synucleinopathy

The cellular dysfunction in LBD is driven by the misfolding and aggregation of a key synaptic protein:

• Alpha-Synuclein Aggregates (Lewy Bodies): Pathological misfolding of **α-synuclein** leads to the formation of insoluble, toxic intracellular aggregates known as **Lewy bodies** in neuronal cell bodies and **Lewy neurites** in neuronal processes.
• Neocortical and Brainstem Infiltration: Unlike Parkinson's Disease, where pathology is initially restricted to the brainstem (substantia nigra), LBD involves early, widespread infiltration of Lewy bodies into the limbic structures and neocortex.
• Severe Cholinergic Deficit: LBD is characterized by a profound loss of cholinergic (acetylcholine-producing) neurons in the **nucleus basalis of Meynert**. This cholinergic depletion is more severe than in Alzheimer's Disease and underlies the fluctuating attention and visual hallucinations.
• Dopaminergic Depletion: Loss of dopaminergic neurons in the **substantia nigra pars compacta** drives the Parkinsonian motor features.

💊 Pharmacotherapy & Neuroleptic Warnings

Treatment focuses on managing cognitive, psychiatric, and motor symptoms, requiring a delicate balance due to severe drug sensitivities.

First-Line Cholinesterase Inhibitors

• Cognitive & Behavioral Support: Donepezil (5-10 mg daily) or **Rivastigmine** (oral or transdermal patch) are first-line therapies. They increase acetylcholine levels, significantly improving cognitive fluctuations, attention, and reducing the frequency of hallucinations.

Parkinsonism Management

• Dopaminergic Therapy: Oral **Levodopa/Carbidopa** is introduced at low doses to treat disabling motor symptoms. Efficacy is often modest compared to Parkinson's Disease, and higher doses can exacerbate visual hallucinations and confusion.

🔬 Active Clinical Trials

Clinical trials are currently evaluating α-synuclein targeted immunotherapies, small-molecule aggregation inhibitors, and novel cognitive enhancers.

🗺️ Next Steps After Diagnosis

If you or a loved one has recently been diagnosed with Lewy Body Dementia, coordinate these care steps:

1. Review Current Medications: Ensure all treating clinicians are aware of the diagnosis to strictly avoid prescribing standard antipsychotics or dopamine antagonists.
2. Initiate Cholinesterase Inhibitor: Discuss starting Donepezil or a Rivastigmine patch with your neurologist to target cognitive fluctuations and visual hallucinations.
3. Confirm REM Sleep parasomnia: If dream-enactment behavior is present, ensure a safe sleeping environment (e.g. padding sharp edges, low bed height) and discuss low-dose Melatonin or Clonazepam.
4. Evaluate for Orthostatic Hypotension: Monitor blood pressure when lying down and standing up. Implement non-pharmacological measures (increased hydration, compression stockings) if orthostatic drops are observed.

❓ Patient FAQ

Q: What is the difference between Lewy Body Dementia (LBD) and Parkinson's Disease Dementia (PDD)?
A: Both conditions involve alpha-synuclein pathology. The difference is based on the timing of symptoms (the "one-year rule"). If cognitive decline and dementia occur before or within one year of the onset of motor symptoms, the diagnosis is **Dementia with Lewy Bodies (DLB)**. If motor symptoms are present for more than one year before dementia begins, it is classified as **Parkinson's Disease Dementia (PDD)**.

Q: Are the visual hallucinations in LBD scary?
A: Surprisingly, no. Hallucinations in LBD are often silent, detailed images of children, adults, or friendly animals. Patients frequently retain insight and realize they are not real, so they do not find them frightening. If they are not causing distress, they should not be treated with high-risk medications.